Advertisement

Current Bladder Dysfunction Reports

, Volume 13, Issue 4, pp 301–308 | Cite as

Salvage Combination Therapies for Refractory Overactive Bladder

  • Sarah Martin
  • Esther Han
  • Jason GilleranEmail author
Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)
  • 44 Downloads
Part of the following topical collections:
  1. Topical Collection on Reconstructed Bladder Function & Dysfunction

Abstract

Purpose of Review

With a high prevalence of overactive bladder (OAB) worldwide and rising health care costs for patients who fail first-, second-, and third-line treatments, there is a growing need to explore novel strategies to address the most refractory cases of OAB. The concept of utilizing combination treatment regimens to maximize efficacy while minimizing morbidity and side effects, in a cost-effective manner, is discussed in this review article.

Recent Findings

A literature review over the last 10 years was performed, focusing on therapies used in combination for OAB including behavioral therapy, pharmacologic therapy, neuromodulation, and botulinum toxin. A separate literature review specifically for augmentation cystoplasty was also undertaken. Such “salvage” treatments suggested in the literature include pharmacologic therapy in combination or with behavioral modification, various forms of neuromodulation with medication, alternative forms of neuromodulation, with or without prior botulinum toxin injections, and lastly, augmentation cystoplasty.

Summary

In this review article, we outline combination therapies such as adding mirabegron to solifenacin, anticholinergic medication in addition to either behavioral therapy or various types of neuromodulation and using neuromodulation after failed botulinum toxin injections are efficacious treatment approaches and have shown to be superior to monotherapy for the treatment non-neurogenic refractory OAB. In the most severe cases of refractory OAB, augmentation cystoplasty remains an option that provides acceptable results in the appropriately selected patient.

Keywords

Overactive bladder Anticholinergics Mirabegron Salvage therapy Neuromodulation Augmentation cystoplasty 

Notes

Compliance with Ethical Standards

Conflict of Interest

Sarah Martin declares that she has no conflict of interest.

Esther Han declares that she has no conflict of interest.

Jason Gilleran declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2017;11:117–25 Available at: https://www.karger.com/Article/FullText/447205. Accessed 1 July 2018.CrossRefGoogle Scholar
  2. 2.
    Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40. Available at: http://www.jmcp.org/doi/10.18553/jmcp.2014.20.2.130. Accessed 7 June 2018.PubMedGoogle Scholar
  3. 3.
    Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urol. 2010;75:526–532.e18 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0090429509023115. Accessed 1 July 2018.
  4. 4.
    •• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. J Urol. 2012;188:2455–2463. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022534712049592. Accessed 13 Aug 2018. Current guideline for OAB treatment.
  5. 5.
    •• Apostolidis A, Averbeck MA, Sahai A, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882–893. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.23170. Accessed 8 Apr 2018. First attempt to create a treatment algorithm for patients with OAB. It discusses AM failures, combination pharmacologic therapy, Botox vs neuromodulation, and augmentation cyoplasty—all of which is discussed in this review article.
  6. 6.
    American Urological Association. Available at: https://www.auanet.org/guidelines/incontinence-non-neurogenic-overactive-bladder-(2012-amended-2014). Accessed 30 Sept 2018.
  7. 7.
    Quirouet A, Goldman HB. Management of overactive bladder refractory to medical therapy. Current Bladder Dysfunction Reports. 2014;9:336–40 Available at: http://link.springer.com/10.1007/s11884-014-0259-2, Accessed 1 July 2018.CrossRefGoogle Scholar
  8. 8.
    • Chancellor MB, Yehoshua A, Waweru C, et al. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. Int Urol Nephrol. 2016;48:1029–1036. Available at: http://link.springer.com/10.1007/s11255-016-1277-0. Accessed 2 July 2018. Results suggest that changing between various AM medications does not improve efficacy of OAB treatment.
  9. 9.
    Komesu YM, Amundsen CL, Richter HE, et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018;218:111.e1–9 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0002937817311882. Accessed 15 July 2018.CrossRefGoogle Scholar
  10. 10.
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. 2015;67:577–88 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0302283814001316. Accessed 2 July 2018.CrossRefGoogle Scholar
  11. 11.
    Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 116:612–622. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.13068. Accessed 2 July 2018.
  12. 12.
    •• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE). Eur Urol. 2016;70:136–145. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0302283816002074. Accessed 2 July 2018. Shows the evidence to suggest the superior efficacy of combination pharmacologic therapy using an AM and beta-3 agonist compared to AM monotherapy.
  13. 13.
    Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health. 2005;8:495–505 Available at: http://linkinghub.elsevier.com/retrieve/pii/S1098301510600435. Accessed 9 July 2018.CrossRefGoogle Scholar
  14. 14.
    Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, et al. Behavior therapy to enable drug discontinuation in the treatment of urge incontinence: a randomized controlled trial. Ann Intern Med. 2008;149:161–9 Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201984/. Accessed 1 July 2018.CrossRefGoogle Scholar
  15. 15.
    Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32:179–84 Available at: http://link.springer.com/10.1007/s00345-013-1112-5. Accessed 9 July 2018.CrossRefGoogle Scholar
  16. 16.
    Tang H, Chen J, Wang Y, et al. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial. Urol J. 2014;11:1800–1805Google Scholar
  17. 17.
    Li X, Liao L, Chen G, Wang Z, Deng H. Combination of sacral nerve and tibial nerve stimulation for treatment of bladder overactivity in pigs. Int Urol Nephrol. 2017;49:1139–45 Available at: http://link.springer.com/10.1007/s11255-017-1587-x. Accessed 15 July 2018.CrossRefGoogle Scholar
  18. 18.
    • Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol. 2018;44:102–108. Available at: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382018000100102&lng=en&tlng=en. Accessed 15 July 2018. Provides evidence to suggest the superiority of combination therapy with PTNS and solifenacin vs either monotherapy alone.
  19. 19.
    Pham K, Guralnick ML, O’Connor RC. Unilateral versus bilateral stage I neuromodulator lead placement for the treatment of refractory voiding dysfunction. Neurourol Urodyn. 27:779–81 Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.20577. Accessed 15 July 2018.
  20. 20.
    Marcelissen TAT, Leong RK, Serroyen J, van Kerrebroeck PEV, de Wachter SGG. The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy. J Urol. 2011;185:976–80 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022534710049669. Accessed 15 July 2018.CrossRefGoogle Scholar
  21. 21.
    Scheepens WA, Bie RAD, Weil EHJ, et al. Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction. J Urol. 2002;168:2046–50.CrossRefGoogle Scholar
  22. 22.
    El-Azab AS, Siegel SW. Specific tips for general controversies in sacral Neuromodulation. Curr Urol Rep. 2016;17. Available at: http://link.springer.com/10.1007/s11934-016-0640-0. Accessed 15 July 2018:79.CrossRefGoogle Scholar
  23. 23.
    • Amundsen CL, Komesu YM, Chermansky C, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxina for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018. Results suggest no evidence of superiority between intradetrusor Botox injections and sacral neuromodulation for the treatment of OAB. Provides pros and cons of both treatment. Google Scholar
  24. 24.
    Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61:834–9 Available at: http://linkinghub.elsevier.com/retrieve/pii/S030228381101373X. Accessed Aug 14 2018.CrossRefGoogle Scholar
  25. 25.
    •• Hoag N, Plagakis S, Pillay S, et al. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxin A treatment. Neurourol Urodyn 36:1377–1381. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.23117. Accessed 15 July 2018. Provides evidence that sacral neuromodulation can still provide symptomatic relief in patients who fail previous intradetrusor Botox injections.
  26. 26.
    Smits M, Oerlemans D, Macelissen T, et al. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. J Urol. 2013;190:2148–52.CrossRefGoogle Scholar
  27. 27.
    Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012;109:1280–93 Available at: https://www.ncbi.nlm.nih.gov/pubmed/22117733.CrossRefGoogle Scholar
  28. 28.
    Veeratterapillay R, Thorpe AC, Harding C. Augmentation cystoplasty: contemporary indications, techniques and complications. Indian J Urol. 2013;29:322–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/24235795.CrossRefGoogle Scholar
  29. 29.
    Department of Health, UK. Hospital Episode Statistics. Department of Health, UK.Google Scholar
  30. 30.
    Shreck E, Gioia K, Lucioni A. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA. Curr Urol Rep. 2016;17:27 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26902621.CrossRefGoogle Scholar
  31. 31.
    Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009: CD004202. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19370596.
  32. 32.
    de Figueiredo AA, Lucon AM, Srougi M. Bladder augmentation for the treatment of chronic tuberculous cystitis. Clinical and urodynamic evaluation of 25 patients after long term follow-up. Neurourol Urodyn. 2006;25:433–40 Available at: https://www.ncbi.nlm.nih.gov/pubmed/16791845.CrossRefGoogle Scholar
  33. 33.
    Shawket TN, Muhsen J. Treatment of bilharzial-contracted bladder by ileocystoplasty or colocystoplasty. J Urol. 1967;97:285–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/6018422.CrossRefGoogle Scholar
  34. 34.
    Sayegh ES, Dimmette RM. The fibrotic contracted urinary bladder associated with schistosomiasis and chronic ulceration: a clinicopathological study including treatment. J Urol. 1956;75:671–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/13307769.CrossRefGoogle Scholar
  35. 35.
    Dounis A, Abel BJ, Gow JG. Cecocystoplasty for bladder augmentation. J Urol. 1980;123:164–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/7354508.CrossRefGoogle Scholar
  36. 36.
    Smith RB, van Cangh P, Skinner DG, et al. Augmentation enterocystoplasty: a critical review. J Urol. 1977;118:35–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/875193.CrossRefGoogle Scholar
  37. 37.
    Shirley SW, Mirelman S. Experiences with colocystoplasties, cecocystoplasties and ileocystoplasties in urologic surgery: 40 patients. J Urol. 1978;120:165–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/671623.CrossRefGoogle Scholar
  38. 38.
    Hradec EA. Bladder substitution: indications and results in 114 operations. J Urol. 1965;94:406–17 Available at: https://www.ncbi.nlm.nih.gov/pubmed/5320331.CrossRefGoogle Scholar
  39. 39.
    Nurse DE, Parry JR, Mundy AR. Problems in the surgical treatment of interstitial cystitis. Br J Urol. 1991;68:153–4 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1822961.CrossRefGoogle Scholar
  40. 40.
    van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone-preserving orthotopic substitution enterocystoplasty for interstitial cystitis. J Urol. 2002;167:603–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11792927.CrossRefGoogle Scholar
  41. 41.
    Webster GD, Maggio MI. The management of chronic interstitial cystitis by substitution cystoplasty. J Urol. 1989;141:287–91 Available at: https://www.ncbi.nlm.nih.gov/pubmed/2913346.CrossRefGoogle Scholar
  42. 42.
    El-Azab AS, Moeen AM. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxin A and augmentation cystoplasty. Arab J Urol. 2013;11:344–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26558103.CrossRefGoogle Scholar
  43. 43.
    Venn SN, Mundy AR. Long-term results of augmentation cystoplasty. Eur Urol. 1998;34(Suppl 1):40–2 Available at: https://www.ncbi.nlm.nih.gov/pubmed/9705554.CrossRefGoogle Scholar
  44. 44.
    • Cheng KC, Kan CF, Chu PS, et al. Augmentation cystoplasty: Urodynamic and metabolic outcomes at 10-year follow-up. Int J Urol. 2015;22:1149–54 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26391472.CrossRefGoogle Scholar
  45. 45.
    Whitmore WF, Gittes RF. Reconstruction of the urinary tract by cecal and ileocecal cystoplasty: review of a 15-year experience. J Urol. 1983;129:494–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/6834531.CrossRefGoogle Scholar
  46. 46.
    Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 2001;88:511–25 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11678743.CrossRefGoogle Scholar
  47. 47.
    Küss R, Bitker M, Camey M, et al. Indications and early and late results of intestino-cystoplasty: a review of 185 cases. J Urol. 1970;103:53–63 Available at: https://www.ncbi.nlm.nih.gov/pubmed/5415722.CrossRefGoogle Scholar
  48. 48.
    George VK, Russell GL, Shutt A, et al. Clam ileocystoplasty. Br J Urol. 1991;68:487–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1747723.CrossRefGoogle Scholar
  49. 49.
    Mitchell ME, Kulb TB, Backes DJ. Intestinocystoplasty in combination with clean intermittent catheterization in the management of vesical dysfunction. J Urol. 1986;136:288–91 Available at: https://www.ncbi.nlm.nih.gov/pubmed/3723679.CrossRefGoogle Scholar
  50. 50.
    Kreder KJ, Webster GD. Management of the bladder outlet in patients requiring enterocystoplasty. J Urol. 1992;147:38–41 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1729548.CrossRefGoogle Scholar
  51. 51.
    Khoury JM, Timmons SL, Corbel L, et al. Complications of enterocystoplasty. Urology. 1992;40:9–14 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1621320.CrossRefGoogle Scholar
  52. 52.
    DeFoor W, Tackett L, Minevich E, et al. Risk factors for spontaneous bladder perforation after augmentation cystoplasty. Urology. 2003;62:737–41 Available at: https://www.ncbi.nlm.nih.gov/pubmed/14550454.CrossRefGoogle Scholar
  53. 53.
    Shekarriz B, Upadhyay J, Demirbilek S, et al. Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology. 2000;55:123–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/10654908.CrossRefGoogle Scholar
  54. 54.
    Hendren WH, Hendren RB. Bladder augmentation: experience with 129 children and young adults. J Urol. 1990;144:445–53 discussion 460. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2374218.CrossRefGoogle Scholar
  55. 55.
    Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172:1649–51 discussion 1651–2. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15371782.CrossRefGoogle Scholar
  56. 56.
    Edlund C, Peeker R, Fall M. Clam ileocystoplasty: successful treatment of severe bladder overactivity. Scand J Urol Nephrol. 2001;35:190–5 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11487070.CrossRefGoogle Scholar
  57. 57.
    Awad SA, Al-Zahrani HM, Gajewski JB, et al. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol. 1998;81:569–73 Available at: https://www.ncbi.nlm.nih.gov/pubmed/9598629.CrossRefGoogle Scholar
  58. 58.
    Beier-Holgersen R, Kirkeby LT, Nordling J. “Clam” ileocystoplasty. Scand J Urol Nephrol. 1994;28:55–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/8009194.CrossRefGoogle Scholar
  59. 59.
    Apostolidis A, Popat R, Harper M, et al. Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty. Nat Clin Pract Urol. 2007;4:280–4 Available at: https://www.ncbi.nlm.nih.gov/pubmed/17483813.CrossRefGoogle Scholar
  60. 60.
    Rasmussen NT, Guralnick ML, O’Connor RC. Successful use of sacral neuromodulation after failed bladder augmentation. Can Urol Assoc J. 2009;3:E49–50 Available at: https://www.ncbi.nlm.nih.gov/pubmed/19829718.CrossRefGoogle Scholar
  61. 61.
    Reyblat P, Ginsberg DA. Augmentation cystoplasty: what are the indications? Curr Urol Rep. 2008;9:452–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/18947509.CrossRefGoogle Scholar
  62. 62.
    Ivancić V, Defoor W, Jackson E, et al. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010;184:1768–74 Available at: https://www.ncbi.nlm.nih.gov/pubmed/20728123.CrossRefGoogle Scholar
  63. 63.
    Reyblat P, Ginsberg DA. Augmentation enterocystoplasty in overactive bladder: is there still a role? Curr Urol Rep. 2010;11:432–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/20734172.CrossRefGoogle Scholar
  64. 64.
    • Watanabe JH, Campbell JD, Ravelo A, et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76:835–40 Available at: https://www.ncbi.nlm.nih.gov/pubmed/20430422.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Urology DetroitDetroit Medical CenterDetroitUSA
  2. 2.Department of Urology Royal OakWilliam Beaumont HospitalRoyal OakUSA

Personalised recommendations